Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma

Journal of Clinical Oncology

Volumn 21, Issue 13, 2003, Pages 2481-2485

  Dhaini, Hassan R ^a   Thomas, Dafydd G ^a   Giordano, Thomas J ^a   Johnson, Timothy D ^a   Biermann, J Sybil ^a   Leu, Kirsten ^a   Hollenberg, Paul F ^a   Baker, Laurence H ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYP3A PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P 450 CYP3A45; CYTOCHROME P-450 CYP3A45; CYTOCHROME P450; TUMOR MARKER;

CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METASTASIS; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; ARTICLE; BIOPSY; BIOSYNTHESIS; CHILD; EVALUATION; FEMALE; GENE EXPRESSION REGULATION; MALE; PATHOLOGY; PREDICTION AND FORECASTING; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOPSY; CHILD; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; OSTEOSARCOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0038352146     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2003.06.015     Document Type: Review

References (39)

1. Helliwell TR: Pathology of Bone and Joint Neoplasms (ed 1). Philadelphia, PA, WB Saunders, 1999
2. Picci P, Ferrari S, Bacci G, et al: Treatment recommendations for osteosarcoma and adult soft tissue sarcomas. Drugs 47:82-92, 1994
3. Bacci G, Ferrari S, Bertoni F, et al: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: An updated report. J Clin Oncol 18:4016-4027, 2000
4. Scotlandi K, Serra M, Nicoletti G, et al: Multidrug resistance and malignancy in human osteosarcoma. Cancer Res 56:2434-2439, 1996
5. Thomas DG, Giordano TJ, Sanders D, et al: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. Clin Cancer Res 8:788-793, 2002
6. Gorlick R, Huvos AG, Heller G, et al: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 17:2781-2788, 1999
7. Park YB, Kim HS, Oh JH, et al: The co-expression of p53 protein and P-glycoprotein is correlated to a poor prognosis in osteosarcoma. Int Orthop 24:307-310, 2001
8. Ueda Y, Dockhorn-Dworniczak B, Blasius S, et al: Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. J Cancer Res Clin Oncol 119:172-178, 1993
9. Shnyder SD, Hayes AJ, Pringle J, et al: P-glycoprotein and metallothionein expression and resistance to chemotherapy in osteosarcoma. Br J Cancer 78:757-759, 1998
10. Uozaki H, Horiuchi H, Ishida T, et al: Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27, and lung resistance-related protein) in osteosarcoma. Relationship with poor prognosis. Cancer 79:2336-2344, 1997
11. Trieb K, Kotz R: Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol 33:11-17, 2001
12. Wunder JS, Bull SB, Aneliunas V, et al: MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol 18:2685-2694, 2000
13. Serra M, Scotlandi K, Reverter-Branchat G, et al: Value of P-glycoprotein and clinicopathologic factors as the basis for new treatment strategies in high-grade osteosarcoma of the extremities. J Clin Oncol 21:536-542, 2003
14. Wrighton SA, VandenBranden M, Ring BJ: The human drug metabolizing cytochromes P450. J Pharmacokinet Biopharm 24:461-473, 1996
15. Parke DV: The cytochromes P450 and mechanisms of chemical carcinogenesis. Environ Health Perspect 102:852-853, 1994
16. Murray GI, Shaw D, Weaver RJ, et al: Cytochrome P450 expression in oesophageal cancer. Gut 35:599-603, 1994
17. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
18. Wang S, Saboorian MH, Frenkel E, et al: Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: Comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 53:374-381, 2000
19. Fisher L, Van Belle G: Biostatistics: A methodology for the Health Sciences, Applied Probability and Statistics. New York, John Wiley and Sons, 1993, pp 329-330
20. Forrester LM, Hayes JD, Millis R, et al: Expression of glutathione S-transferases and cytochrome P450 in normal and tumor breast tissue. Carcinogenesis 11:2163-2170, 1990
21. McKay JA, Murray GI, Weaver RJ, et al: Xenobiotic metabolising enzyme expression in colonic neoplasia. Gut 34:1234-1239, 1993
22. Murray GI, McFadyen MC, Mitchell RT, et al: Cytochrome P450 CYP3A in human renal cell cancer. Br J Cancer 79:1336-1842, 1999
23. Murray GI, McKay JA, Weaver RJ, et al: Cytochrome P450 expression is a common molecular event in soft tissue sarcomas. J Pathol 171:49-52, 1993
24. Murray GI, Taylor MC, Burke MD, et al: Enhanced expression of cytochrome P450 in stomach cancer. Br J Cancer 77:1040-1044, 1998
25. Watanabe J, Shimada T, Gillam EM, et al: Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 10:25-33, 2000
26. Murray GI, Melvin WT, Greenlee WF, et al: Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41:297-316, 2001
27. Murray GI: The role of cytochrome P450 in tumour development and progression and its potential in therapy. J Pathol 192:419-426, 2000
28. Shimada T, Hayes CL, Yamazaki H, et al: Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 56:2979-2984, 1996
29. Zheng W, Xie DW, Jin F, et al: Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 9:147-150, 2000
30. Nallani SC, Genter MB, Desai PB: Increased activity of CYP3A enzyme in primary cultures of rat hepatocytes treated with docetaxel: Comparative evaluation with paclitaxel. Cancer Chemother Pharmacol 48:115-122, 2001
31. Berthou F, Dreano Y, Belloc C, et al: Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol 47:1883-1895, 1994
32. Li AP, Kaminski DL, Rasmussen A: Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8, 1995
33. Good P: Permutation Tests: A Practical Guide to Resampling Methods for Testing Hypothesis. Springer, New York City, NY, 1994, pp. 29-31
34. Schmitz-Drager BJ, Goebell PJ, Eben T, et al: p53 immunohistochemistry as a prognostic marker in bladder cancer. Playground for urology scientists? Eur Urol 38:691-699, discussion 700, 2000
35. Marx D, Meden H, Ziemek T, et al: Expression of the p53 tumour suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer. Eur J Cancer 34:845-850, 1998
36. Pochanugool L, Subhadharaphandou T, Dhanachai M, et al: Prognostic factors among 130 patients with osteosarcoma. Clin Orthop (345):206-214, 1997
37. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20:776-790, 2002
38. Miyoshi Y, Ando A, Takamura Y, et al: Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int J Cancer 97:129-132, 2002
39. Lewis AD, Lau DH, Duran GE, et al: Role of cytochrome P-450 from the human CYP3A gene family in the potentiation of morpholino doxorubicin by human liver microsomes. Cancer Res 52:4379-4384, 1992